GLP-1 receptor agonists (GLP-1 RAs), including semaglutide, have become wildly popular for managing type 2 diabetes and weight loss, but emerging research suggests these medications carry an unexpected long-term trade-off: improved surgical recovery paired with increased risks to bone and joint health. As five- and ten-year follow-up data become available, orthopedic surgeons are raising important questions about what patients taking these drugs should watch for. What Are GLP-1 Medications and Why Are They So Popular? GLP-1 receptor agonists are a class of diabetes and weight-loss medications that work by mimicking a natural hormone that helps regulate blood sugar and appetite. They've exploded in use since 2019, particularly among people with type 2 diabetes and obesity. The appeal is clear: these drugs deliver proven benefits in blood sugar control, weight loss, and reducing heart disease risk. But as more people take them long-term, researchers are discovering effects that weren't visible in shorter studies. Do GLP-1 Drugs Actually Help With Surgery Recovery? Here's the good news first. A major study examining over a decade of surgical data found that patients taking GLP-1 medications before common orthopedic procedures experienced measurable benefits. Researchers analyzed ten of the most frequently performed orthopedic surgeries, including total knee replacements, total hip replacements, shoulder replacements, and spinal fusions, comparing outcomes between GLP-1 users and non-users from 2010 to 2023. The results were encouraging. Across multiple major procedures, GLP-1 use was associated with significantly lower odds of emergency department visits after surgery. Patients taking these medications also showed lower surgical site infection rates following knee and hip replacements. For knee replacement patients specifically, revision rates (the need for repeat surgery) were lower among GLP-1 users. These improvements held true regardless of obesity severity. What Are the Long-Term Bone Health Risks? The concerning findings emerged from a separate five-year study tracking bone and joint complications. Researchers compared nearly 73,500 patients with type 2 diabetes and obesity who were taking GLP-1 medications against matched controls who were not. After five years, the differences in bone health outcomes were statistically significant. - Osteoporosis Risk: GLP-1 users developed osteoporosis at a rate of 4.1% compared to 3.2% in the control group, representing a 29% increased risk. Osteoporosis weakens bones and increases fracture risk, particularly in older adults. - Gout Incidence: GLP-1 users experienced gout at a rate of 7.4% versus 6.6% in non-users, a 12% higher risk. Gout is a painful form of arthritis caused by uric acid crystal buildup in joints. - Osteomalacia Cases: The most striking finding was osteomalacia, a bone-softening disease caused by vitamin D deficiency. GLP-1 users developed this condition at a rate of 2% compared to just 0.1% in controls, representing a 155% increased risk. "We are just now reaching the precipice where five- and ten-year follow-up data are becoming available for patients taking GLP-1 medications," said Muaaz Wajahath, a fourth-year medical student at Michigan State University College of Human Medicine and primary investigator of the osteoporosis study. Muaaz Wajahath, Fourth-Year Medical Student, Michigan State University College of Human Medicine Why Might GLP-1 Drugs Affect Bone Health? The exact mechanisms aren't fully understood yet, but researchers have several theories. Rapid weight loss from GLP-1 medications can affect bone density, since bones adapt to changes in body weight. Additionally, these drugs may influence how the body absorbs or processes nutrients like vitamin D and calcium, which are essential for bone strength. The increased gout risk may relate to how GLP-1 medications affect uric acid metabolism. Because these medications are relatively new in widespread use, the long-term effects on bone metabolism are still being studied. How to Monitor Your Bone Health If You Take GLP-1 Medications - Baseline Bone Density Screening: If you're starting a GLP-1 medication and have risk factors for osteoporosis (such as being over 50, having a family history of osteoporosis, or being postmenopausal), ask your doctor about a bone density scan (DEXA scan) before beginning treatment. - Regular Vitamin D and Calcium Monitoring: Ensure adequate intake of vitamin D and calcium through diet or supplementation. Your doctor can check your vitamin D levels with a simple blood test to catch deficiency early, which could prevent osteomalacia. - Watch for Gout Symptoms: Be alert to sudden joint pain, redness, or swelling, particularly in the big toe, ankle, or knee. Report these symptoms to your doctor promptly, as early treatment can prevent chronic gout. - Annual Check-ins With Your Care Team: Schedule regular appointments with both your primary care doctor and, if possible, an orthopedic specialist or rheumatologist who understands GLP-1 use. They can monitor for delayed-onset complications and adjust your treatment plan as needed. "Whenever you have a patient who is prone to osteoporosis, gout or osteomalacia, clinicians should consider bone health surveillance and monitor for delayed-onset complications in at-risk populations. These changes can be implemented immediately and can be an easy fix to potentially prevent these side effects," explained Wajahath. Muaaz Wajahath, Fourth-Year Medical Student, Michigan State University College of Human Medicine What Should Patients Do Right Now? If you're taking a GLP-1 medication for type 2 diabetes or weight loss, this research doesn't mean you should stop your medication. The benefits for blood sugar control and heart health remain significant. Instead, use this information to have a proactive conversation with your healthcare provider. Discuss your personal risk factors for osteoporosis, gout, and vitamin D deficiency. Ask about baseline bone density screening if appropriate for your age and health profile. Make sure your doctor knows you're taking a GLP-1 medication, especially if you're planning orthopedic surgery, since the improved surgical outcomes could be relevant to your care. The research presented at the 2026 American Academy of Orthopedic Surgeons Annual Meeting represents an important milestone: we're finally getting long-term data on medications that have been adopted at unprecedented speed. As Wajahath noted, any medication seeing this rapid adoption warrants close examination, particularly when long-term effects on bone and joint health remain poorly understood. The good news is that bone health complications are largely preventable with proper monitoring and early intervention.
